Overview
A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management
Status:
Completed
Completed
Trial end date:
2015-12-01
2015-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.Phase:
Phase 4Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Antonios LikourezosTreatments:
Ketorolac
Ketorolac Tromethamine
Criteria
Inclusion Criteria:Severe flank and abdominal pain, severe musculoskeletal pain (traumatic and non-traumatic
in origin), headache, dental pain.
Exclusion Criteria:
Age >65, Active Peptic Ulcer disease, Acute Gastrointestinal Hemorrhage, Known Hx of Renal
or Hepatic insufficiency, Hx of allergies to NSAIDS.